A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs PDR 001 (Primary) ; WNT 974 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Novartis
- 24 Feb 2017 PDR-001 primary drug has been added hence treatment arms also increases from 1 to 2.
- 24 Feb 2017 Planned End Date changed from 1 Jan 2019 to 10 Jan 2020.
- 24 Feb 2017 Planned primary completion date changed from 1 Jan 2019 to 25 Sep 2018.